Cancer BiologyiSciencePeer-reviewed
Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors
Giorgia Anastasio, Michela Felaco, Alessia Lamolinara…·Luca Cardone
This paper shows that low-dose decitabine combined with olaparib enhances antitumor activity in KRAS-dependent pancreatic ductal adenocarcinoma, regardless of BRCA1/2 status.
1 citation